CIO 2025 will be held in Miami, Florida, October 17 to 19.

The Symposium on Clinical Interventional Oncology (CIO) is the ultimate destination for clinicians passionate about advancing cancer through interventional oncology (IO).

Designed for practicioners at every stage of their IO journey, CIO delivers a comprehensive curriculum that spans foundational techniques to the latest innovations in robotics, systemic treatments, and emerging therapies.

‍

Spend a weekend with experts in Miami and learn how the EPIONE^® robotic platform will impact your clinical practice.

If you would like a more personalized demo, contact us at info@quantumsurgical.com and let the Quantum Surgical Team introduce you to EPIONE^®, the all-in-one robotic platform designed to plan, target, deliver and confirm percutaneous ablation procedures..

‍

We look forward to seeing you in Miami!

‍

Event Details

Date :

• October 17-19, 2025

Location :

• Loews Miami Beach, Florida

‍

The Journées Francophones de Radiologie 2025 will be held from October 3rd to 6th in Palais des Congrès de Paris (Porte Maillot, Paris, France).

Do not miss your chance to meet with all the key players in Radiology!

Explore Epione^®, our unique robotic-assisted platform empowering physicians to Plan, Target, Deliver, and Confirm tumor ablation.

‍

• Visit us at Quantum Surgical Booth at the Village de Radiologie Interventionnelle (3rd floor).‍
  
  • You can already set-up a meeting with out team for a personalized Epione^® demo. Request a demo – Quantum Surgical or email us at info@quantumsurgical.com
    
• Discover Epione^® during the Super Demo sessions hosted by some of our top users at the Agora of the Village de Radiologie Interventionnelle (information coming soon).

‍

Event Details:

• Date: October 3-6th, 2025
• Location:  Porte Maillot, Paris, France
• Learn more about the JFR 2025

‍

WAIS 2025 will be held in Colorado Springs, CO, September 20-24, 2025.

The Western Angiographic & Interventional Society (WAIS) is celebrating its 55 year anniversary in 2025!

WAIS hosts an annual conference that focuses on a single general session format to connect faculty and attendees through interactive discussions and shared experiences. The 2025 Program is designed to address clinician practice gaps, as well as introduce emerging trends in image-guided therapies, patient care, and technology.

‍

Quantum Surgical will exhibit Epione^®,  the all-in-one robotic-assisted  solution which allows physicians to plan, target, deliver and confirm tumor ablation by combining the power of Navigation, Robotic-Assistance and Ablation Confirmation.

Please stop by our booth to meet with the Quantum Surgical team – we look forward to seeing you at the event!

Learn more about WAIS 2025.

Date:

• 20-24 September 2025

Location :

• The Broadmoor – Colorado Springs, Colorado

‍

Organized by the Cardiovascular and Interventional Radiology Society of Europe, the CIRSE 2025 event is the world's biggest meeting focusing on interventional radiology and will take place in Barcelona, Spain from September 13-17, 2025.

For 40 years, the CIRSE annual congress has provided the world’s premier platform for specialists in minimally invasive image-guided procedures to meet, share and connect. Quantum Surgical is delighted to announce its renewed participation this year, underscoring our commitment to advancing medical innovation and collaboration within this dynamic community.

Explore Epione^®, our unique robotic-assisted platform empowering physicians to Plan, Target, Deliver, and Confirm tumor ablation.

‍

Visit us at Quantum Surgical Booth.
You can already set-up a meeting with out team for a personalized Epione^® demo. Request a demo – Quantum Surgical or email us at info@quantumsurgical.com

Event Details:

• Date: September 13-17, 2025
• Location: Centre de Convencions International de Barcelona, Spain

‍

The European Conference on Interventional Oncology 2025 will be held in Rotterdam, The Netherlands, from April 13th to 16th, 2025.

Organized by the CIRSE, this yearly event brings together interventional radiologists, medical oncologists, surgeons, and numerous other healthcare professionals around the latest advancements in Interventional Oncology.

Don’t miss the opportunity to learn more about the Epione^®, a unique robotic-assisted platform, at the ECIO:

• ORAL PRESENTATION – Preliminary results of the EPIBONE study

Dr. Baptiste Bonnet – Gustave Roussy (Villejuif, France)
Tuesday, April 15th I 8:30 AM – 10:00 AM

• ORAL PRESENTATION – Irreversible electroporation of liver lesions with robotic assistance: feasibility, safety and oncology outcome in a series of 22 cases

Prof. Laurent Milot – Hôpital Edouard Herriot, Hospices Civils de Lyon (Lyon, France)
Tuesday, April 15th I 5:00 PM – 6:30 PM

• e-POSTER – Safety and Accuracy of Robotic-Assisted Microwave ablation: first American experience on 50 patients

Dr. Govindarajan Narayanan – Baptist Health (Miami, USA)

• e-POSTER – Performance and safety of robotic-assisted CT-guided percutaneous ablation in lungs – Final results of the EGLE study

Dr. Baptiste Bonnet et al. – Gustave Roussy (Villejuif, France)

‍

Visit us at Quantum Surgical Booth.
You can already set-up a meeting with out team for a personalized Epione^® demo. Request a demo – Quantum Surgical or email us at info@quantumsurgical.com

‍

Détails de l'événement :

• Date: April 13-16, 2025
• Location: Rotterdam Ahoy Convention Centre – Rotterdam, The Netherlands

The SIO 2025 Annual Scientific Meeting will be held in Las Vegas, NV, from January 30th to February 3rd, 2025.

We are excited to announce our active participation in the Society of Interventional Oncology (SIO) 2025 Annual Scientific Meeting.

As a dedicated non-profit association, the Society of Interventional Oncology continues to champion the advancement of interventional oncology (IO), positioning it as the fourth pillar of cancer therapy worldwide. The SIO 2025 Annual Scientific Meeting stands as the pinnacle of gatherings in interventional oncology, showcasing the latest research, fostering longitudinal learning, hosting insightful tumor boards, and providing invaluable networking opportunities with colleagues and industry professionals.

Over the span of five enriching days, dive into a realm of new skills, forge meaningful relationships, and elevate patient-care practices. Join us at our booth for a firsthand experience of our groundbreaking solutions. Learn more about Epione^®, our unique robotic-assisted platform that empowers physicians to Plan, Target, Deliver, and Confirm tumor ablation.

• Don’t miss the chance to register for the SIO hands-on workshops, designed to deepen your expertise:
  “Robotics, Navigation, Guidance, and Confirmation Hands-on”: “Image Guidance & Robotics”
  Sunday February 2nd,  January 26th, 2:30pm – 3:45pm

Visit us at our booth throughout the event, from January 31st to February 2nd, for a captivating hands-on demonstration. Experience firsthand how Epione^® is revolutionizing the field of interventional oncology.

Nous nous réjouissons de vous voir à cet événement.

To register for SIO 2025, please visit: Annual Scientific Meeting

‍

Date :

• January 30th – February 2nd, 2025

Localisation :

• Paris Las Vegas, Las Vegas, Nevada

Montpellier, April 24, 2025 – The Léon Bérard Center (CLB), a cancer treatment center in Lyon, has just installed Epione^®, the platform developed by Quantum Surgical that enables early and curative treatment of tumors. The first patients have already been treated. CLB becomes the sixth site in France to offer this minimally invasive treatment, which destroys abdominal and lung tumors by inserting a needle through the skin.

Specializing in robotics and artificial intelligence, Quantum Surgical develops the Epione robotic platform, which enables physicians to perform safe and effective percutaneous tumor ablations. This minimally invasive treatment is an alternative to surgery, involving the insertion of one or more needles through the skin to reach and destroy the tumor.

Epione has already been used to treat 875 patients worldwide and is now available at Léon Bérard Center in Lyon.

“The adoption of the Epione robot marks a major advancement for our department and our patients. Thanks to this cutting-edge technology, we can perform minimally invasive procedures with unmatched precision, thereby reducing risks and significantly improving patient care. This innovation strengthens our commitment to providing the highest quality of care in interventional radiology,” explains Dr. Amine Bouhamama, interventional radiologist at the Léon Bérard Center.

“At the Léon Bérard Center, we are deeply committed to offering our patients ever more advanced and compassionate care. We are therefore proud to integrate the innovation represented by Epione into our therapeutic options, providing our patients with procedures that are more precise, less invasive, and safer,” says Professor Jean-Yves Blay, General Director of the Léon Bérard Center.

“We are delighted with this new installation at the Léon Bérard Center. The deployment of a second Epione just weeks after the one at Toulouse University Hospital is a true validation of the benefits our platform offers. The entire Quantum Surgical team is thrilled that more patients can now benefit from our technology to treat their tumors,” says Bertin Nahum, President and Co-founder of Quantum Surgical.

Epione is CE-marked in Europe for abdominal and lung tumors and FDA-approved in the United States for abdominal tumors. Epione is available in about 20 hospitals worldwide including at Baptist Health South Florida in Miami, Florida and Rush University System Health in Chicago, Illinois.

About Quantum Surgical

Quantum Surgical is a French medical robotics company co-founded in 2017 by Bertin Nahum, CEO. With a dynamic team of over 130 employees, the company is headquartered in Montpellier, France, and has offices in Miami, Florida.

Its Epione^® platform is dedicated to the curative and early treatment of cancers. Quantum Surgical thus offers a new approach to cancer treatment by standardizing access to care. More patients can benefit from innovative, better targeted and less invasive treatments. Hundreds of patients have already been treated worldwide.

Quantum Surgical was awarded the prestigious Prix Galien USA in 2022, the equivalent of the Nobel Prize for biopharmaceutical research, and joined in 2023 the governmental French Tech 2030 program that supports top emerging actors in disruptive innovation.

More information: www.quantumsurgical.com

About the Léon Bérard Center (CLB)

The Léon Bérard Center is a member of the Unicancer network, which brings together 18 French Cancer Centers and one affiliated institution. It is recognized as a regional, national, and international center of excellence in oncology. Located in Lyon, one of France’s major cities, the CLB fulfills a threefold mission of care, research, and education, with a constant focus on improving the quality and accessibility of cancer care.

All diagnostic tests, treatments, and patient follow-up during and after illness are provided on a single site. The Center receives more than 45,000 patients each year for hospital stays, consultations, or examinations, and diagnoses over 6,000 new tumors annually.

The CLB has over 2,200 staff members, including 280 physicians, 600 researchers, and 800 caregivers. One of the Center’s strengths is its seamless integration of care and research. On-site, doctors and researchers work closely together to shorten the time between laboratory discoveries and their application to patient care. As a result, more than 2,000 patients are enrolled each year in one of the 300 open clinical trials.

Press contact Léon Bérard Center

Julie Colomb

julie.colomb@lyon.unicancer.fr

Tél.: +33 (0)4 69 85 61 85

‍

London and Montpellier, June 10th, 2025 – King’s College Hospital NHS Foundation Trust has installed Quantum Surgical’s Epione^® robotic platform. King’s College Hospital NHS Foundation Trust has become the first center in the UK to adopt this innovative technology to treat early-stage cancerous tumors.

Quantum Surgical, a company specializing in robotics and AI, develops the Epione^® robotic platform. It assists physicians in performing percutaneous tumor ablations, where one or more needles are inserted through the skin to destroy the tumor. This minimally invasive treatment provides patients with a safe and effective alternative to surgery.

King’s College Hospital NHS Foundation Trust patients have benefited from these percutaneous ablation techniques for over 20 years. Thanks to Epione, King’s College Hospital can now offer patients with liver cancer this robotic-assisted technology that enhances the safety and accuracy of these procedures. Seven patients have already been treated by Dr. Praveen Peddu and his team.

Dr. Praveen Peddu, Consultant Interventional Radiologist at King’s College Hospital, explains: “Compared with conventional percutaneous ablations, this type of robotic ablation is less invasive and more precise. Patients treated with this new technology can benefit from less post-operative pain, shorter stays in hospital and better outcomes, recovering at home  in a few days. We are delighted to be able to expand the types of percutaneous minimally invasive ablative treatments for cancer we can offer to our patients at King’s, helping us improve cancer treatment and care.”

Robotic-assisted mini-invasive treatments can help the patient’s recovery with shorter hospital stay (outpatient procedure possible and reduced pain and side effects.

“We are very proud of the first installation of our Epione robotic system in the United Kingdom. We are delighted to work with King’s College Hospital NHS Foundation Trust, Dr. Peddu and his colleagues are paving the way for physicians in the UK who will be able to offer more patients to benefit from innovative and less invasive treatments, and improve their lives” declares Bertin Nahum, President and co-founder of Quantum Surgical.

Epione is currently used to treat tumors in the liver in about twenty cancer centers worldwide. Over 900 patients have already been treated worldwide.

‍

Montpellier and Taiwan, March 20^th 2025 – A specialist in the minimally invasive treatment of cancerous tumors, Quantum Surgical extends its presence in Taiwan in partnership with Unison Healthcare Group. Quantum Surgical’s robotic platform Epione is already used in fifteen cancer centers in Europe and in the USA.

Quantum Surgical develops the Epione^® robotic platform. It assists physicians in performing percutaneous tumor ablations, where one or more needles are inserted through the skin to destroy the tumor. This minimally invasive treatment provides patients with a safe and effective alternative to surgery.

Epione can treat tumors located in the abdomen (liver, kidney, pancreas) in the lungs, and is currently used to treat tumors in the liver in about fifteen cancer centers worldwide. Over 800 patients have already been treated worldwide.

Quantum Surgical now partners with UHG to strategically expand activities in Taiwan, according to the latest statistics, the number of newly diagnosed cancer cases in Taiwan in 2022 is estimated to be 132,293, an increase of 8,531 cases compared to 2021.

Bertin Nahum, CEO and co-founder of Quantum Surgical explains “We are thrilled to expand our activities in Taiwan with Unison Healthcare Group, as our mission is to improve early-stage cancer treatment worldwide and ensure that as many cancer patients as possible can benefit from our minimally invasive technology”.

Daniel Shih, Chairman and President of Unison Healthcare Group (UHG) declares ”The partnership between UHG and Quantum Surgical’s founders began with their former venture Medtech and the ROSA surgical robot. The Group is honored to work with Quantum Surgical again to promote the minimally invasive surgical robotic system for cancer treatment. We hope that the new generation of minimally invasive cancer surgical robots will elevate the quality of Taiwan’s cancer treatment industry”.

‍

À propos de Quantum Surgical

Quantum Surgical is a French medical robotics company co-founded in 2017 by Bertin Nahum, CEO. With a dynamic team of over 10 employees, the company is headquartered in Montpellier, France, and has offices in Miami, Florida.

Its Epione^® platform is dedicated to the curative and early treatment of cancers. Quantum Surgical thus offers a new approach to cancer treatment by standardizing access to care. More patients can benefit from innovative, better targeted and less invasive treatments. Hundreds of patients have already been treated worldwide.

Quantum Surgical was awarded the prestigious Prix Galien USA in 2022, the equivalent of the Nobel Prize for biopharmaceutical research, and joined in 2023 the governmental French Tech 2030 program that supports top emerging actors in disruptive innovation.

Plus d'informations : www.quantumsurgical.com

‍

About Unison Healthcare Group

Founded in 1995, Unison Healthcare Group (UHG) has always been committed to providing the highest quality healthcare services in Taiwan by upholding the brand mission of “Inspiring Healthcare for Happiness”. Since the introduction of radiological equipment in the 1960s, the Group has continued to expand from “precision diagnosis” to “precision medicine”. In 2009, UHG embarked on the era of medical robots, and has been distributing a number of high-end surgical robots for neurosurgery, orthopedics, and other medical fields, which has revolutionized the delivery of healthcare and clinical services. Meanwhile, the Group has also developed a “one-stop comprehensive service” to provide medical institutions, private organizations and individuals with a genuine “Total/Integrated Solution” for medical and healthcare services. Moreover, UHG is fully committed to promoting ESG and obtained the B Corp Certification in 2022.

‍

Press contact Unison Healthcare Group

Athena Liu

athenaliu@unison.com.tw

Tel: +886-939392092

Montpellier, February 27th 2025 – Quantum Surgical, manufacturer of the Epione^® platform for robotic-assisted percutaneous ablations, is proud to announce the expansion of its Scientific Advisory Board (SAB) with the appointment of  Sean Tutton, MD, FSIR, FCIRSE, a board-certified diagnostic and interventional radiologist who specializes in the treatment of cancer and non-cancer related pathologic skeletal fractures at UC San Diego Health. This appointment is a key milestone for Quantum Surgical and the company’s commitment to advancing innovation in robotic-assisted procedures for interventional radiologists and expanding access to patient care.

Interventional oncology has become highly specialized and is rapidly becoming a standard of care for many multidisciplinary cancer programs. Considered the fourth pillar of oncology, the growth of this subspecialty is similar to the evolution of surgical oncology.

“Robotics has long been established in surgical fields such as general surgery, urology, and orthopedics, so its integration into interventional radiology is a natural progression,” said Dr. Sean Tutton.

“Robotic-guided procedures in interventional oncology offer significant value to physicians, but it’s the patients who really gravitate to robotics because there is the perception of the precision, efficacy, and safety,” adds Dr. Tutton.

The Epione platform is an advanced robotic-assisted technology designed for interventional radiologists performing percutaneous ablations of abdominal tumors—a minimally invasive treatment often used with curative intent. It enhances physician support by providing real-time patient monitoring, assisting in planning an optimal trajectory, improving tumor targeting precision, increasing the accuracy of therapy delivery, and offering immediate confirmation of procedural success.

“As we continue to focus on our clinical strategy of robotic-assisted procedures, we are honored with the appointment of Dr. Sean Tutton to expand our SAB of world-renowned experts in interventional oncology. His expertise and insight will support our vision of driving the demand for minimally invasive cancer care in the US market,” says Bertin Nahum, CEO and co-founder of Quantum Surgical.

“We are honored to welcome Dr. Sean Tutton to our SAB,” said Laetitia Messner, Chief Clinical Officer at Quantum Surgical. “His expertise and insights will be invaluable in shaping Quantum Surgical’s clinical strategy and driving the adoption of Epione.”

Quantum Surgical’s Scientific Advisory Board brings together a distinguished, multidisciplinary team of global experts dedicated to advancing robotic-assisted interventional oncology. The board includes:

• Govindarajan Narayanan, MD (USA), Chief of Interventional Oncology at Miami Cardiac and Vascular Institute Miami Cancer Institute, a part of Baptist Health South Florida
• Steven D. Colquhoun, MD (USA), Professor of Surgical Oncology, Wellstar MCG Health Medical Center (Augusta, GA)
• Thierry De Baère, MD (France), Professor and Interventional Radiologist at Gustave Roussy Cancer Center (Villejuif)
• Laurent Milot, MD (France), Professor and Deputy Chief Vascular & Interventional Radiology at the Hospices Civils de Lyon
• Luigi Solbiati, MD, (Italy), Professor of Radiology at Humanitas University (Rozzano – Milan) (Honorary Member)

‍

À propos de Quantum Surgical

Quantum Surgical is a French medical robotics company co-founded in 2017 by Bertin Nahum, CEO. With a dynamic team of over 120 employees, the company is headquartered in Montpellier, France, and has offices in Miami, Florida.

Quantum Surgical was awarded the prestigious Prix Galien USA in 2022, the equivalent of the Nobel Prize for biopharmaceutical research, and joined the governmental French Tech 2030 program in 2023, which supports top emerging actors in disruptive innovation.

The Epione platform is designed to standardize cancer care by enabling earlier and more precise interventional oncology procedures. It is FDA-cleared for CT-guided percutaneous ablation procedures in the abdomen, CE-marked for ablations in the abdomen and lung, and compatible with most ablation devices.

Plus d'informations : www.quantumsurgical.com

It’s been a busy and exciting year at Quantum Surgical. Here are some of our highlights:

• The Paoli-Calmettes Institute in Marseille, France, acquired Epione. About 30 patients have since been treated by Dr Piana and his team.
• Quantum Surgical received €30 million financing from the European Investment Bank.
• Quantum Surgical launched the Epibone clinical study to assess Epione^®’s performance to treat bone tumors.
• Rush University System for Health in Chicago (IL) acquired Epione^®.
• Dr. Naranayan and his team celebrated the 150th patient treated at Baptist Health, Miami (FL).
• Quantum Surgical received the French National Institute of Industrial Property Award in the Start-up category.
• Quantum Surgical organized a webinar with the Baptist Health IO team.
• Quantum Surgical’s first symposiums took place in USA at Spectrum in Miami and in Europe at ECIO in Mallorca, Spain.
• Quantum Surgical obtained ISO 27001:2023 certification which attests to the security and rigor of its data management system.
• Bertin Nahum, CEO and co-founder, spoke at CES in Las Vegas, the biggest tech event in the world.
• Lucien Blondel, our CTO and co-founder, received the Surgical Robotics Industry Award of Industry Leadership.
• LSI Europe invited Quantum Surgical to present the Epione^® solution in Lisbon, Portugal.
• Quantum Surgical and Epione^® attended various events worldwide: Spectrum in Miami, FL; ECIO in Mallorca, Spain; CIRSE in Lisbon, Portugal; Medpeers in Amsterdam, The Netherlands…
• And 720+ patients have been treated overall!

We are really happy with everything we have achieved together as a team and with our partners, we look forward to 2025!

‍

Montpellier, February 4, 2025 – As part of its STARThu program, the Toulouse University Hospital (CHU) has just acquired Epione^®, the robot from Quantum Surgical designed to assist physicians in the curative and early treatment of abdominal and lung tumors. The CHU is the first center in Occitanie to offer patients this minimally invasive, safe, and effective surgery.

To destroy an abdominal or lung tumor, a percutaneous tumor ablation (through the skin) can be performed. This is a minimally invasive radiological procedure aimed at destroying the cancerous tumor using a needle, either through heat or cold. Therefore, it is essential to guide this needle precisely to the location of the tumor. This process is often long and challenging, as tumors can be small and “poorly located.”

This is where the robotic platform Epione^® comes into play. Using imaging technology, the Epione^® robot assists physicians by:

• Visualizing the area to be treated with a 2D/3D image fusion software and ensuring the precise positioning of the ablation needle.
• Confirming the success of the treatment.

For patients, this means access to a safe, effective, and minimally invasive treatment.

As part of its STARThu plan, the Toulouse University Hospital (CHU) has acquired Epione^® to further develop robot-assisted procedures within its facilities, aiming to offer ever more advanced treatments to its patients. With this acquisition, the CHU becomes the fifth center in France to offer this innovative treatment.

Jean-François Lefebvre, General Manager of Toulouse University Hospital (CHU) : By integrating robotic solutions like Epione^® in interventional imaging, the Toulouse University Hospital reaffirms its commitment to medical and technological innovation. This major advancement reflects our ongoing dedication to offering our patients less invasive, yet increasingly precise and effective treatments, particularly in oncology. I would like to commend Professor Mokrane and his teams for implementing this cutting-edge technology. As part of its 2023-2028 institutional project and through the STARThu plan (Strategic Plan for Robotic and Technological Interventional Assistance in University Hospitals), the CHU of Toulouse confirms its status as a leading reference center, ensuring both modernity and medical excellence.”

Professor Fatima Mokrane, radiologist at Toulouse University Hospital (CHU), explains: “Epione^® is a unique therapeutic solution that allows us to treat early-stage and hard-to-reach tumors in a minimally invasive and highly precise manner. Thanks to this technology, we will be able to treat more patients in Toulouse, and in a more comfortable way.”

Bertin Nahum, President and Co-founder of Quantum Surgical, states: “We are delighted with this new acquisition by the Toulouse University Hospital, the first in Occitanie. The entire Quantum Surgical team is thrilled that our technology is now accessible to more patients for the treatment of their tumors.”

‍

À propos de Quantum Surgical

Quantum Surgical is a French medical robotics company co-founded in 2017 by Bertin Nahum, CEO. With a dynamic team of over 120 employees, the company is headquartered in Montpellier, France, and has offices in Miami, Florida.

Its Epione^® platform is dedicated to the curative and early treatment of cancers. Quantum Surgical thus offers a new approach to cancer treatment by standardizing access to care. More patients can benefit from innovative, better targeted and less invasive treatments. Hundreds of patients have already been treated worldwide.

Quantum Surgical a reçu le prestigieux Prix Galien USA en 2022, l'équivalent du Prix Nobel pour la recherche biopharmaceutique, et a rejoint en 2023 le programme gouvernemental French Tech 2030 qui soutient les meilleurs acteurs émergents en matière d'innovation de rupture.

Plus d'informations : www.quantumsurgical.com

‍

About the Toulouse University Hospital (CHU de Toulouse)

The Toulouse University Hospital (CHU) is a leading healthcare and academic institution, deeply rooted in the city of Toulouse and the Occitanie region. It fulfills its public service missions by providing medical care and prevention, training future healthcare professionals, and actively contributing to innovation and medical research.

In the field of oncology, the CHU dedicates up to 25% of its overall activity to cancer treatment. Its healthcare services are organized across three hospital sites labeled as “Institut Universitaire du Cancer – Toulouse”:

• IUCT-Rangueil-Larrey
• IUCT-Purpan
• IUCT-Oncopole

These sites operate in a complementary manner, avoiding duplication and promoting a multidisciplinary and coordinated approach to cancer treatment.

In western Occitanie, the CHU de Toulouse handles 39% of all cancer-related hospitalizations, making it the leading center for oncology care in the region. With 1,244 patients enrolled in clinical trials and 456 active research projects, the CHU is strongly committed to advancing knowledge and treatments to better meet patients’ needs.

Ranked the best hospital in France (Le Point 2024 ranking), the CHU de Toulouse is also one of the largest employers in the Occitanie region, with a workforce of 16,000 professionals, including 4,000 physicians and 12,000 hospital staff, whose expertise and dedication drive its excellence.

‍

Press contact Toulouse University Hospital (CHU)

Joséphine Enard
Enard.j@chu-toulouse.fr
Tel. : +33 (0)5 61 77 80 27

‍

Chicago and Miami, November 12, 2024 – Rush University System for Health, a nationally recognized leader in providing high-quality care, announced today that it has acquired QuantumSurgical’s Epione®p latform. Rush University Medical Center is among a select group of hospitals nationwide — and the first in the Midwest — to adopt this innovative technology.

The Epione platform is a state-of-the-art robotic-assisted technology for interventional radiologists who perform percutaneous ablations of abdominal tumors, a minimally invasive treatment often used with curative intent. Epione supports physicians in planning the optimal targeting of a tumor and monitoring the patient’s position in real-time. The robotic arm uses this information to precisely position the physician’s instrumentation. This enables increased accuracy of the ablation procedure and allows for immediate confirmation if the tumor ablation was successful.

“Rush’s interventional radiology program is one of the best programs in the country, excelling in clinical interventional care, education with one of the largest and most sought-after residency programs, and robust research activities with multiple ongoing clinical trials,” says Bulent Arslan, MD,FSIR, director of vascular and interventional radiology at Rush. “We are very happy to be first in the region to provide this new technology to our patients that will make their experience better, more efficient, and safer. Robotic systems have been in surgical care for many years and now are available for the interventional care of patients. We treat complex lesions throughout the body with ablative therapies, but it is not always easy to reach our targets, and there is some risk involved in the process. Using Epione, we will be able to reach most locations with computerized guidance using patients’ existing CT or MRI images relatively easily and with less risk. This is an evolution in cancer patient care, and we are excited to be the first in the Chicago area to offer it.”

While surgery may be an option for some, it often involves higher costs and longer hospital stays. Epione is a minimally invasive option for patients with small tumors. Patients can often go home the same day with nothing more than a Band-Aid.

"We are thrilled to celebrate this milestone as Quantum Surgical’s Epione platform arrives in the Midwest," said Bertin Nahum, CEO and Co-founder of Quantum Surgical. "We are excited to collaborate with the esteemed team at Rush University System for Health, as our mission is to ensure that as many cancer patients as possible can benefit from this minimally invasive technology."

About Quantum Surgical

Quantum Surgical was founded in 2017 by CEO and co-founder Bertin Nahumand a team of pioneering innovators specializing in developing and commercializing advanced medical robotics. Headquartered in Montpellier, France, and Miami, Florida, Quantum Surgical has a growing team of over 120 dedicated professionals.

The Epione platform is designed to revolutionize cancer care by enabling earlier and more precise treatments. Epione is FDA-cleared for CT-guided percutaneous ablation procedures in the abdomen and is compatible with most FDA-approved ablation devices.

More information: www.quantumsurgical.com

Press Contact Quantum Surgical

Stéphanie Moy          

s.moy@quantumsurgical.com

Tel.: +33 (0)6 32 55 85 48

About Rush

Rush University System for Health brings together the brightest minds in medicine, research and academics. Driven by discovery, innovation and a deep responsibility for the health of our communities, RUSH is a national leader in outstanding patient care, education, research and community partnerships and in empowering a new generation of health care providers.

RUSH is a nonprofit health system that includes Rush University Medical Center, Rush University, Rush Copley Medical Center and Rush Oak Park Hospital, as well as an extensive provider network and numerous outpatient care facilities. Rush University Medical Center is ranked among the top hospitals in the nation by U.S. News & World Report and consistently is named among the top academic medical centers for excellence in patient care by Vizient Inc. anda Top Teaching Hospital by The Leapfrog Group. Rush University comprises three colleges: Rush Medical College, the College of Nursing and the College ofHealth Sciences. 

‍

Montpellier, September 19, 2024 – Quantum Surgical is launching a new clinical study for the treatment of bone tumors and metastases, assisted by the Epione® platform. Conducted in parallel at the Paoli-Calmettes Institute (Marseille) and the Hospices Civils de Lyon, the study is coordinated by Dr. Baptiste Bonnet, an interventional radiologist at Gustave Roussy (Villejuif), ranked fourth best cancer hospital in the world in 2023[1].This study will evaluate the clinical performance and safety of the Epione platform for treating these lesions.

Although primary bone cancer is relatively rare, the development of bone metastases—often occurring several months or years after the initial cancer—is common, affecting one-third of cancer patients[2].

Specializing in medical robotics and artificial intelligence, Quantum Surgical develops the Epione technology, which enables physicians to perform safe and effective percutaneous tumor ablations. This minimally invasive treatment involves inserting one or more needles through the skin and into the tumor to destroy it.

Epione is CE marked for ablation indications in the abdomen and lung, and FDA-cleared for ablation indications in the abdomen. More than 575 patients have benefited from this curative treatment worldwide.

This new clinical study “Epibone” will assess the performance of the Epione platform to treat bone tumors and metastases, with the ultimate goal of obtaining an extension of its market approvals in Europe and the United States.

“This study is a new step in the development of Quantum Surgical, and I am pleased that it is being conducted with three of our valued partners, whose teams are well acquainted with our technology and its potential to treat more patients,” explains Bertin Nahum, CEO and Co-founder of Quantum Surgical.

“The Epibone study represents a significant advance in the evolution of robot-assisted guidance, focusing on a topic that is close to our hearts: percutaneous bone procedures. It is likely one of the most ambitious and relevant indications forthe Epione robotic platform!” elaborates Dr. Baptiste Bonnet, Interventional Radiologist at Gustave Roussy.

Laetitia Messner, Clinical Director at Quantum Surgical, adds: “We are really eager to validate the effectiveness of Epione in treating bone lesions. Given that one-third of cancer patients suffer from bone metastases, many patients could benefit from our innovative technology.”

Epione is currently used at the Gustave Roussy Cancer Center in Villejuif, the Hospices Civils de Lyon, the Paoli-Calmettes Institute in Marseille, and the CHU Amiens-Picardie.

Epione is also used in Miami and recently available in two renowned cancer centers in the USA.

About Quantum Surgical                                                                              

Quantum Surgical is a French company specializing in medical robotics and AI,co-founded in 2017 by Bertin Nahum, CEO. With a dynamic team of over 110 employees, the company is headquartered in Montpellier, France, and has offices in Miami, Florida. Its Epione platform is dedicated to the curative and early treatment of cancers.

Quantum Surgical offers a new approach to cancer treatment by standardizing access to care. More patients can benefit from innovative, better-targeted, and less invasive treatments. Hundreds of patients have already been treated worldwide.

Quantum Surgical was awarded the prestigious Prix Galien USA in 2022, the equivalent of the Nobel Prize for biopharmaceutical research, and joined the governmental French Tech 2030 program in 2023, which supports top emerging actors in disruptive innovation.

More information: www.quantumsurgical.com

[1] GustaveRoussy, 2023

[2] InfoCancer

‍

‍Montpellier, August 7th 2024 – To better understand public apprehension towards cancer and their knowledge of treatments, the medical robotics company Quantum Surgical surveyed them. Conducted on both sides of the Atlantic, the YouGov study reveals that a majority of American and French citizens fear that future generations will suffer from cancer, unlike Germans. Additionally, over half of the American believe that robotic solutions can enhance cancer treatments. However, data also shows that percutaneous ablation, a minimally invasive technique significantly reducing recovery time, is still relatively unknown in the U.S.

Cancer: A Major Concern for a Majority of American People

While the WHO predicts a 77%increase in cancer cases worldwide by 2050 ^[1], 53% of Americans fear being diagnosed with cancer, a concern shared by the French (54%). Furthermore, over half of American people express concern for the young people close to them; the concern reaches nearly two-thirds in France. This contrasts significantly with Germany, where only 37% fear for their younger generations.

Even more surprising: 47% of Americans aged 18 to 24 express concerns about future generations, compared to 74% of young French.

Americains and French More Confident Than Germans in Robotics to EnhanceCancer Treatments

A majority of Americans and French perceive robotics as an effective solution to improve cancer treatments (56% and 53%r espectively). This enthusiasm is particularly notable among American men (59% compared to 52% among women). Similar gender disparities exist in France where it reaches the significant disparity of 63% versus 44%.

In contrast, only 44% of German respondents believe that robotics is an effective solution to improve cancer treatments.

 “The WHO’s predictions suggest that cancer will unfortunately be a reality for many people. The fact that the majority of Americans believe that robotics and AI can make cancer treatments more effective is very encouraging. At Quantum Surgical, we have demonstrated with Epione® how technology can concretely assist physicians in improving cancer treatmentfor patients,” said Bertin Nahum, President and Co-founder of QuantumSurgical.

Percutaneous Ablation: A Future Solution Little Known in the United States Compared to OtherCountries

Only7% of American respondents are familiar with percutaneous ablation as a cancer treatment method, a figure that rises to 11% among cancer patients. This percentage is significantly lower than the 23% of French who report knowing about this new form of therapy and is similar to Germans (6%).

In fact, percutaneous ablation is the least known cancer treatment among the Americans, in comparison to other therapies: 77% are familiar with chemotherapy, 68% with surgery, 59% with bone marrow transplant, 53%with radiotherapy, 35% with immunotherapy and 30% hormone therapy.

This technique, currently under recognized and underutilized globally, offers numerous benefits. Bertin Nahum, CEO and co-fondateur de Quantum Surgical, explains, “The challenge now is to democratize assisted percutaneous ablation, a minimally invasive technique that destroys cancerous tumors by inserting one or more needles through the skin. The patient benefits of these minimally invasive treatments are manifold: fewer complications and pain post-procedure, reduced scarring, shorter hospital stays, and faster recovery.

Epione® is CE marked in Europe for abdominal and lung tumors, and FDA authorized for abdominal tumors. Epione® is available at the Miami Cancer Institute and Miami Cardiac & Vascular Institute, part of Baptist Health South Florida, and three hospitals in France.

Alcohol Consumers Less Anxious… in France!

What about the respondent profiles? In the U.S., 57% and 58% of smokers and heavy alcohol consumers fear being diagnosed with cancer. This statistic drops at 45% in Germany for both categories. Surprisingly, in France, while 57%of smokers fear future cancer diagnosis, only 45% of heavy alcohol consumers share this concern. However, the link between alcohol consumption and cancer is clearly established. It is responsible for 7.1% of cancers in Europe ^[1] and approximately 6% of all cancers and 4% of all cancer deaths in the United States ^[2].

Methodology

The Quantum Surgical study was conducted online from February 20 to 21, 2024 with over 4,000 respondents in France, Germany, and the United States.

About Quantum Surgical                                                                              

Quantum Surgical is a French company specialized in medical robotics and AI, co-founded in 2017 by Bertin Nahum, CEO. With a dynamic team of over 110 employees, the company is headquartered in Montpellier, France, and has offices in Miami, Florida. Its Epione® platform is dedicated to the curative and early treatment of cancers.

Quantum Surgical thus offers a new approach to cancer treatment by standardizing access to care. More patients can benefit from innovative, better targeted and less invasive treatments. Hundreds of patients have already been treated worldwide.

Quantum Surgical was awarded the prestigious Prix Galien USA in 2022, the equivalent of the Nobel Prize for biopharmaceutical research, and joined in 2023 the governmental French Tech 2030 program in 2023 that supports top emerging actors in disruptive innovation.

For more information : www.quantumsurgical.com

Press Contact Quantum Surgical

Stéphanie Moy
s.moy@quantumsurgical.com
Tel. : +33(0)6 32 55 85 48

‍

Join Quantum Surgical and leading experts from Miami Cardiac and Vascular Institute, Miami Cancer Institute, a part of Baptist Health South Florida for a webinar on robotic-assisted ablation for abdominal tumors. Learn how cutting-edge robotic technology is transforming minimally invasive treatments and building a pioneering interventional oncology program in the U.S.

The guest speakers include Govindarajan Narayanan, MD, Chief of Interventional Oncology, Constantino Santiago Peña, MD; Ripal Gandhi, MD; Gina Landinez, MD; and Daniela Garcia, MD, Fellow.

Interventional oncology continues to play a pivotal role in addressing the increasing demands of the growing oncology market. With more patients being diagnosed earlier, the need for safe, efficient, and minimally invasive treatment options has never been greater. As hospitals seek cost-effective solutions, the demand for innovative cancer treatments rises steadily. Robotic-assisted technologies like Epione^® are standardizing care delivery, offering enhanced precision, efficiency, and patient outcomes in treating abdominal tumors through percutaneous ablation.

Click here to register for our webinar featuring the first hospital in the US to adopt robotic-assisted technology and hear how it’s changed their approach in interventional cancer care.

‍